NR4A1 and breast carcinoma: In a separate breast cancer study [66], including 358 patients with invasive breast cancer (mostly stage I–II) and 452 controls, GRAIL also reported, for symptomatically diagnosed breast cancer patients, average sensitivity values of 58%, 40%, and 15%, respectively, in triple negative, HER2-positive/hormone receptor-positive, and HER2-negative breast cancer subtypes, at 95% specificity.